A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces

PLoS Computational Biology

Volumn 11, Issue 10, 2015, Pages

  Porta Pardo, Eduard ^a   Garcia Alonso, Luz ^b   Hrabe, Thomas ^a   Dopazo, Joaquin ^c,d   Godzik, Adam ^a  

^a BURNHAM INSTITUTE   (United States)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENES; TUMORS;

CANCER GENOME; CELLULAR PATHWAY; CLINICAL INFORMATION; INTERACTION INTERFACE; MUTATION DISTRIBUTION; PROTEIN INTERACTION; PROTEIN-PROTEIN INTERACTIONS; SPECIFIC INTERFACE;

PROTEINS;

ALGORITHM; ANALYTIC METHOD; ARTICLE; DISEASE ASSOCIATION; E DRIVER; MALIGNANT NEOPLASTIC DISEASE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR GENE; ANIMAL; BIOLOGICAL MODEL; CHROMOSOMAL MAPPING; COMPUTER SIMULATION; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; MOLECULAR GENETICS; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PROCEDURES; PROTEIN ANALYSIS; PUBLICATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

TUMOR MARKER; TUMOR PROTEIN;

ANIMALS; BASE SEQUENCE; BIOMARKERS, TUMOR; CATALOGS AS TOPIC; CHROMOSOME MAPPING; COMPUTER SIMULATION; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN INTERACTION MAPPING; SIGNAL TRANSDUCTION;

EID: 84946093141     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004518     Document Type: Article

References (78)

1. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177–183. 14993899
2. Cancer Genome Atlas Research N (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519–525. doi: 10.1038/nature11404 22960745
3. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70. doi: 10.1038/nature11412 23000897
4. Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337. doi: 10.1038/nature11252 22810696
5. Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615. doi: 10.1038/nature10166 21720365
6. International Cancer Genome CHudson TJ, Anderson W, Artez A, Barker AD, et al. (2010) International network of cancer genome projects. Nature 464: 993–998. doi: 10.1038/nature08987 20393554
7. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068. doi: 10.1038/nature07385 18772890
8. Cancer Genome Atlas Research N (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43–49. doi: 10.1038/nature12222 23792563
9. Cancer Genome Atlas Research N (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059–2074. doi: 10.1056/NEJMoa1301689 23634996
10. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, et al. (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26: 319–330. doi: 10.1016/j.ccr.2014.07.014 25155756
11. Cancer Genome Atlas Research N (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511: 543–550. doi: 10.1038/nature13385 25079552
12. Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159: 676–690. doi: 10.1016/j.cell.2014.09.050 25417114
13. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202–209. doi: 10.1038/nature13480 25079317
14. Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507: 315–322. doi: 10.1038/nature12965 24476821
15. Cancer Genome Atlas N (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576–582. doi: 10.1038/nature14129 25631445
16. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, et al. (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158: 929–944. doi: 10.1016/j.cell.2014.06.049 25109877
17. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, et al. (2013) Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 3: 2650. doi: 10.1038/srep02650 24084849
18. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, et al. (2012) MuSiC: identifying mutational significance in cancer genomes. Genome Res 22: 1589–1598. doi: 10.1101/gr.134635.111 22759861
19. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505: 495–501. doi: 10.1038/nature12912 24390350
20. Gonzalez-Perez A, Lopez-Bigas N, (2012) Functional impact bias reveals cancer drivers. Nucleic Acids Res 40: e169. doi: 10.1093/nar/gks743 22904074
21. Tamborero D, Gonzalez-Perez A, Lopez-Bigas N, (2013) OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29: 2238–2244. doi: 10.1093/bioinformatics/btt395 23884480
22. Porta-Pardo E, Godzik A, (2014) e-Driver: a novel method to identify protein regions driving cancer. Bioinformatics 30: 3109–3114. doi: 10.1093/bioinformatics/btu499 25064568
23. Leiserson MD, Vandin F, Wu HT, Dobson JR, Eldridge JV, et al. (2014) Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet.
24. Garcia-Alonso L, Jimenez-Almazan J, Carbonell-Caballero J, Vela-Boza A, Santoyo-Lopez J, et al. (2014) The role of the interactome in the maintenance of deleterious variability in human populations. Mol Syst Biol 10: 752. doi: 10.15252/msb.20145222 25261458
25. Reimand J, Bader GD, (2013) Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol 9: 637. doi: 10.1038/msb.2012.68 23340843
26. Ryslik GA, Cheng Y, Cheung K-H, Modis Y, Zhao H, (2013) Utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics 14.
27. Lahiry P, Torkamani A, Schork NJ, Hegele RA, (2010) Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 11: 60–74. doi: 10.1038/nrg2707 20019687
28. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, et al. (2014) Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet 46: 939–943. doi: 10.1038/ng.3051 25086664
29. Jonsson PF, Bates PA, (2006) Global topological features of cancer proteins in the human interactome. Bioinformatics 22: 2291–2297. 16844706
30. AlQuraishi M, Koytiger G, Jenney A, MacBeath G, Sorger PK, (2014) A multiscale statistical mechanical framework integrates biophysical and genomic data to assemble cancer networks. Nat Genet 46: 1363–1371. doi: 10.1038/ng.3138 25362484
31. Nishi H, Tyagi M, Teng S, Shoemaker BA, Hashimoto K, et al. (2013) Cancer missense mutations alter binding properties of proteins and their interaction networks. PLoS One 8: e66273. doi: 10.1371/journal.pone.0066273 23799087
32. Espinosa O, Mitsopoulos K, Hakas J, Pearl F, Zvelebil M, (2014) Deriving a mutation index of carcinogenicity using protein structure and protein interfaces. PLoS One 9: e84598. doi: 10.1371/journal.pone.0084598 24454733
33. Woo SR, Corrales L, Gajewski TF, (2015) Innate Immune Recognition of Cancer. Annu Rev Immunol.
34. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N, (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160: 48–61. doi: 10.1016/j.cell.2014.12.033 25594174
35. Cancer Genome Atlas Research NWeinstein JN, Collisson EA, Mills GB, Shaw KR, et al. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45: 1113–1120. doi: 10.1038/ng.2764 24071849
36. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214–218. doi: 10.1038/nature12213 23770567
37. Mosca R, Ceol A, Aloy P, (2013) Interactome3D: adding structural details to protein networks. Nat Methods 10: 47–53. doi: 10.1038/nmeth.2289 23399932
38. Brooks AN, Kilgour E, Smith PD, (2012) Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18: 1855–1862. doi: 10.1158/1078-0432.CCR-11-0699 22388515
39. Barcellos KS, Bigarella CL, Wagner MV, Vieira KP, Lazarini M, et al. (2013) ARHGAP21 protein, a new partner of alpha-tubulin involved in cell-cell adhesion formation and essential for epithelial-mesenchymal transition. J Biol Chem 288: 2179–2189. doi: 10.1074/jbc.M112.432716 23235160
40. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, et al. (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24: 743–750. doi: 10.1101/gr.165985.113 24782321
41. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, et al. (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225–1235. doi: 10.1038/ni.1655 18820683
42. Janelle V, Langlois MP, Tarrab E, Lapierre P, Poliquin L, et al. (2014) Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunol Res 2: 200–206. doi: 10.1158/2326-6066.CIR-13-0173 24778316
43. Rolland T, Tasan M, Charloteaux B, Pevzner SJ, Zhong Q, et al. (2014) A proteome-scale map of the human interactome network. Cell 159: 1212–1226. doi: 10.1016/j.cell.2014.10.050 25416956
44. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, et al. (2013) TCPA: a resource for cancer functional proteomics data. Nat Methods 10: 1046–1047.
45. Hao Y, Wang C, Cao B, Hirsch BM, Song J, et al. (2013) Gain of interaction with IRS1 by p110alpha-helical domain mutants is crucial for their oncogenic functions. Cancer Cell 23: 583–593. doi: 10.1016/j.ccr.2013.03.021 23643389
46. Follis AV, Llambi F, Ou L, Baran K, Green DR, et al. (2014) The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat Struct Mol Biol 21: 535–543. doi: 10.1038/nsmb.2829 24814347
47. Nehrt NL, Peterson TA, Park D, Kann MG, (2012) Domain landscapes of somatic mutations in cancer. BMC Genomics 13 Suppl 4: S9. doi: 10.1186/1471-2164-13-S4-S9 22759657
48. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, et al. (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515: 572–576. doi: 10.1038/nature14001 25428506
49. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, et al. (2014) HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2: 522–529. doi: 10.1158/2326-6066.CIR-13-0227 24894089
50. Porta-Pardo E, Hrabe T, Godzik A, (2014) Cancer3D: understanding cancer mutations through protein structures. Nucleic Acids Res.
51. Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B, (2014) Synonymous mutations frequently act as driver mutations in human cancers. Cell 156: 1324–1335. doi: 10.1016/j.cell.2014.01.051 24630730
52. Jaroszewski L, Li Z, Cai XH, Weber C, Godzik A, (2011) FFAS server: novel features and applications. Nucleic Acids Res 39: W38–44. doi: 10.1093/nar/gkr441 21715387
53. Xu D, Jaroszewski L, Li Z, Godzik A, (2014) AIDA: ab initio domain assembly server. Nucleic Acids Res 42: W308–313. doi: 10.1093/nar/gku369 24831546
54. Porta-Pardo E, Godzik A, (2015) Analysis of individual protein regions provides novel insights on cancer pharmacogenomics. PLoS Comput Biol 11: e1004024. doi: 10.1371/journal.pcbi.1004024 25568936
55. Zhong Q, Simonis N, Li QR, Charloteaux B, Heuze F, et al. (2009) Edgetic perturbation models of human inherited disorders. Mol Syst Biol 5: 321. doi: 10.1038/msb.2009.80 19888216
56. Sahni N, Yi S, Zhong Q, Jailkhani N, Charloteaux B, et al. (2013) Edgotype: a fundamental link between genotype and phenotype. Curr Opin Genet Dev 23: 649–657. doi: 10.1016/j.gde.2013.11.002 24287335
57. Ryan CJ, Cimermancic P, Szpiech ZA, Sali A, Hernandez RD, et al. (2013) High-resolution network biology: connecting sequence with function. Nat Rev Genet 14: 865–879. doi: 10.1038/nrg3574 24197012
58. Wang X, Wei X, Thijssen B, Das J, Lipkin SM, et al. (2012) Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol 30: 159–164. doi: 10.1038/nbt.2106 22252508
59. Sahni N, Yi S, Taipale M, Fuxman Bass JI, Coulombe-Huntington J, et al. (2015) Widespread macromolecular interaction perturbations in human genetic disorders. Cell 161: 647–660. doi: 10.1016/j.cell.2015.04.013 25910212
60. Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, et al. (2011) Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Annals of Oncology 22.
61. Ryan CJ, Lord CJ, Ashworth A, (2014) DAISY: picking synthetic lethals from cancer genomes. Cancer Cell 26: 306–308. doi: 10.1016/j.ccr.2014.08.008 25203319
62. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957–959. doi: 10.1126/science.1229259 23348506
63. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, et al. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45: 1127–1133. doi: 10.1038/ng.2762 24071851
64. Liu Y, Zhang X, Han C, Wan G, Huang X, et al. (2015) TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520: 697–701. doi: 10.1038/nature14418 25901683
65. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, et al. (2010) Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26: 2069–2070. doi: 10.1093/bioinformatics/btq330 20562413
66. Shoemaker BA, Zhang D, Thangudu RR, Tyagi M, Fong JH, et al. (2010) Inferred Biomolecular Interaction Server—a web server to analyze and predict protein interacting partners and binding sites. Nucleic Acids Res 38: D518–524. doi: 10.1093/nar/gkp842 19843613
67. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database—2009 update. Nucleic Acids Res 37: D767–772. doi: 10.1093/nar/gkn892 18988627
68. Chatr-Aryamontri A, Breitkreutz BJ, Oughtred R, Boucher L, Heinicke S, et al. (2015) The BioGRID interaction database: 2015 update. Nucleic Acids Res 43: D470–478. doi: 10.1093/nar/gku1204 25428363
69. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808–815. doi: 10.1093/nar/gks1094 23203871
70. Lee I, Lehner B, Crombie C, Wong W, Fraser AG, et al. (2008) A single gene network accurately predicts phenotypic effects of gene perturbation in Caenorhabditis elegans. Nat Genet 40: 181–188. doi: 10.1038/ng.2007.70 18223650
71. Aranda B, Blankenburg H, Kerrien S, Brinkman FS, Ceol A, et al. (2011) PSICQUIC and PSISCORE: accessing and scoring molecular interactions. Nat Methods 8: 528–529. doi: 10.1038/nmeth.1637 21716279
72. Kotlyar M, Pastrello C, Pivetta F, Lo Sardo A, Cumbaa C, et al. (2015) In silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods 12: 79–84. doi: 10.1038/nmeth.3178 25402006
73. Iakoucheva LM, Brown CJ, Lawson JD, Obradović Z, Dunker AK, (2002) Intrinsic Disorder in Cell-signaling and Cancer-associated Proteins. Journal of Molecular Biology 323: 573–584. 12381310
74. Kohler S, Bauer S, Horn D, Robinson PN, (2008) Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 82: 949–958. doi: 10.1016/j.ajhg.2008.02.013 18371930
75. Jia P, Zhao Z, (2014) VarWalker: personalized mutation network analysis of putative cancer genes from next-generation sequencing data. PLoS Comput Biol 10: e1003460. doi: 10.1371/journal.pcbi.1003460 24516372
76. Jerby-Arnon L, Pfetzer N, Waldman YY, McGarry L, James D, et al. (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 158: 1199–1209. doi: 10.1016/j.cell.2014.07.027 25171417
77. Hofree M, Shen JP, Carter H, Gross A, Ideker T, (2013) Network-based stratification of tumor mutations. Nat Methods 10: 1108–1115. doi: 10.1038/nmeth.2651 24037242
78. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, et al. (2013) Architecture and membrane interactions of the EGF receptor. Cell 152: 557–569. doi: 10.1016/j.cell.2012.12.030 23374350